Aktis Oncology (AKTS) Financials: Revenue & Earnings
AKTS$16.79+0.34 +2.08%
$902.49M
Market Cap
-15.64
P/E
—
Forward P/E
65
Score
Aktis Oncology (AKTS) Financials: Revenue & Earnings
AKTS price $16.79 +0.34 +2.08%
- Ticker
- AKTS
- Price
- $16.79
- Change
- +0.34 +2.08%
- Market cap ?
- $902.49M
- P/E ?
- -15.64
- Dividend yield ?
- 0.00%
- Beta ?
- 0.45
- Sector
- Healthcare
- Industry
- Biotechnology
- Stocklytics score
- 65
- Value
- 48
- Quality
- 47
- Growth
- 100
Stocklytics score rationale: value 48, quality 47, growth 100.
Financials
| 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|
| 0 | 0 | 1487000 | 6497000 |
Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a…
Fair value
AKTS fair value Not meaningful. Price $16.79.
Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.
Not meaningful
Earnings
| Date | EPS actual | EPS estimate | Revenue | Revenue estimate |
|---|---|---|---|---|
| 2026-11-12 | — | -0.47 | — | 4.02M |
| 2026-08-13 | -0.44 | -0.43 | 3.38M | 2.63M |
| 2026-05-11 | -0.38 | -0.31 | 3.23M | 1.93M |
| 2026-03-30 | -18.19 | -21.59 | 1.87M | 3.28M |
| 2025-12-03 | -1.39 | -0.11 | 4.61M | 12.43M |
| 2024-11-14 | -0.04 | -0.10 | — | 9.30M |
| 2024-10-08 | — | -0.11 | — | 8.20M |
| 2024-05-13 | -0.14 | -0.12 | — | 6.99M |
| 2024-02-13 | -0.19 | -0.18 | — | 8.44M |
| 2023-11-13 | -0.26 | -0.18 | — | 6.99M |
| 2023-09-06 | -0.21 | -0.17 | — | 7.52M |
| 2023-05-08 | -0.20 | -0.19 | — | 5.93M |
| 2022-09-12 | -0.26 | -0.19 | — | 4.70M |
| 2022-01-31 | -0.23 | -0.20 | — | 2.50M |
| 2021-11-01 | -0.25 | -0.20 | — | 2.25M |
Dividends
Yield 0.00%. Payout ratio 0.00%. Frequency —.
Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.
| Ex-date | Dividend | Record | Payment | Frequency |
|---|---|---|---|---|
| No data yet. | ||||
Insider trades
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-09-23 | Czibere Akos | Sell | 12.50K | $4.95 | 61.88K |
| 2026-09-23 | Czibere Akos | Buy | 12.50K | $4.95 | 61.88K |
| 2026-09-23 | Czibere Akos | Sell | 5.10K | $20.19 | 102.97K |
| 2026-09-23 | Czibere Akos | Sell | 7.40K | $21.03 | 155.65K |
| 2026-07-20 | Herrmann Ken | Sell | 1.35K | $1.91 | 2.58K |
| 2026-07-20 | Herrmann Ken | Buy | 1.35K | $1.91 | 2.58K |
| 2026-07-20 | Herrmann Ken | Buy | 3.51K | $0.08 | 280 |
| 2026-07-20 | Herrmann Ken | Sell | 3.51K | $24.56 | 86.12K |
| 2026-07-20 | Herrmann Ken | Sell | 1.35K | $24.56 | 33.16K |
| 2026-07-20 | Herrmann Ken | Sell | 3.51K | $0.08 | 280 |
| 2026-07-17 | Herrmann Ken | Sell | 3.06K | $0.08 | 245 |
| 2026-07-17 | Herrmann Ken | Buy | 3.06K | $0.08 | 245 |
| 2026-07-17 | Herrmann Ken | Sell | 3.06K | $25.21 | 77.26K |
| 2026-07-08 | Ron-Bigger Shulamit | Sell | 50.00K | $3.66 | 183.00K |
| 2026-07-08 | Ron-Bigger Shulamit | Buy | 50.00K | $3.66 | 183.00K |
| 2026-07-08 | Ron-Bigger Shulamit | Sell | 15.80K | $27.13 | 428.68K |
| 2026-07-08 | Ron-Bigger Shulamit | Sell | 30.00K | $27.94 | 838.14K |
| 2026-07-08 | Ron-Bigger Shulamit | Sell | 4.20K | $28.75 | 120.74K |
| 2026-07-08 | Czibere Akos | Sell | 50.00K | $4.95 | 247.50K |
| 2026-07-08 | Czibere Akos | Buy | 50.00K | $4.95 | 247.50K |
| 2026-07-08 | Czibere Akos | Sell | 14.80K | $27.13 | 401.48K |
| 2026-07-08 | Czibere Akos | Sell | 30.83K | $27.95 | 861.74K |
| 2026-07-08 | Czibere Akos | Sell | 4.37K | $28.71 | 125.48K |
| 2026-01-12 | ELI LILLY & Co | Other | 0 | — | — |
Institutional holders
Latest filed quarter: Q2 2026.
Institutions holding: 116, holders +47 vs prior quarter. Ownership 62.12%.
| Holder | Shares | Change | Change % | Value |
|---|---|---|---|---|
| MPM BIOIMPACT LLC | 4.84M | 0 | 0.00% | 155.86M |
| ECOR1 CAPITAL, LLC | 4.82M | 0 | 0.00% | 155.49M |
| BLUE OWL CAPITAL HOLDINGS LP | 3.07M | -91.13K | -2.88% | 98.95M |
| BLACKROCK, INC. | 2.28M | 166.23K | +7.87% | 73.43M |
| T. ROWE PRICE INVESTMENT MANAGEMENT, INC. | 2.05M | -72.36K | -3.41% | 66.12M |
| WELLINGTON MANAGEMENT GROUP LLP | 1.97M | -350.80K | -15.14% | 63.37M |
| RTW INVESTMENTS, LP | 1.59M | 0 | 0.00% | 51.31M |
| RA CAPITAL MANAGEMENT, L.P. | 1.31M | -188.68K | -12.55% | 42.36M |
| JUPITER TOPCO LLC | 1.31M | 1.31M | New | 42.36M |
| BAKER BROS. ADVISORS LP | 996.35K | 0 | 0.00% | 32.11M |
| OCTAGON CAPITAL ADVISORS LP | 960.85K | 0 | 0.00% | 30.97M |
| MERCK & CO., INC. | 952.84K | 0 | 0.00% | 30.71M |
| VANGUARD CAPITAL MANAGEMENT LLC | 817.08K | -16.84K | -2.02% | 26.33M |
| PRICE T ROWE ASSOCIATES INC /MD/ | 763.50K | -800.70K | -51.19% | 24.61M |
| TCG CROSSOVER MANAGEMENT, LLC | 696.56K | 696.56K | New | 22.45M |
| GEODE CAPITAL MANAGEMENT, LLC | 520.74K | 28.80K | +5.85% | 16.79M |
| EVENTIDE ASSET MANAGEMENT, LLC | 507.00K | 0 | 0.00% | 16.34M |
| AVIDITY PARTNERS MANAGEMENT LP | 484.20K | 15.63K | +3.34% | 15.61M |
| STATE STREET CORP | 484.01K | 55.76K | +13.02% | 15.60M |
| A16Z CAPITAL MANAGEMENT, L.L.C. | 415.00K | 0 | 0.00% | 13.38M |
| ALYESKA INVESTMENT GROUP, L.P. | 290.00K | 0 | 0.00% | 9.35M |
| FMR LLC | 285.63K | -100.75K | -26.07% | 9.21M |
| ARROWMARK COLORADO HOLDINGS LLC | 245.87K | -83.60K | -25.37% | 7.92M |
| NORTHERN TRUST CORP | 180.57K | 31.10K | +20.81% | 5.82M |
| SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. | 166.84K | 166.84K | New | 5.38M |
Earnings and financials
Aktis Oncology, Inc. (AKTS) trades at $16.79, with a market cap of $902.49M and a trailing P/E of -15.64. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.
Financials
| 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|
| 0 | 0 | 1487000 | 6497000 |
Insights · Dividends · Forecast · Financials · Learn